Myopia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Myopia – Drugs In Development, 2024 report and make more profitable business decisions.
Myopia, a form of nearsightedness, is a ophthalmological disorder that results in blurred vision when looking at distant objects. This occurs due to the improper refraction of light in the eye, causing the focal point to fall in front of the retina, rather than on it. Close-up objects can still be seen clearly. The underlying cause of myopia can be attributed to specific alterations in the SCO2 gene. Its inheritance pattern follows an autosomal dominant model, indicating that an individual carrying a single mutated copy of the gene is sufficient to manifest the condition. This genetic variation plays a pivotal role in the development of nearsightedness, impacting how the eye focuses light, ultimately affecting vision clarity.
The Myopia drugs in development market research report provide comprehensive information on the therapeutics under development for Myopia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myopia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Myopia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 28 molecules, with 27 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Myopia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Myopia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Myopia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aier Health Eye Drops (Liaoning) Co LtdArctic Vision Shanghai Biotechnology Co Ltd
Bausch & Lomb Inc
BrightGene Bio-Medical Technology Co Ltd
Cellix Bio Pvt Ltd
Cloudbreak Therapeutics LLC
ImPact Biotech Limited
iVeena Delivery Systems Inc
IVIEW Therapeutics Inc
Jenivision Inc
Jiangsu Hengrui Medicine Co Ltd
Nanjing Ruinian Best Pharmaceutical Co Ltd
Novaliq GmbH
Ocumension Therapeutics Co Ltd
Plex Pharmaceuticals Inc
Qilu Pharmaceutical Co Ltd
Santen Pharmaceutical Co Ltd
Seinda Pharmaceutical Guangzhou Corp
Shenyang Sinqi Pharmaceutical Co Ltd
Stuart Therapeutics Inc
Sunhawk Vision Biotech Inc
Sydnexis Inc
Theialife Sciences Pvt Ltd
University of Oklahoma
Vyluma Inc
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd
Zhejiang Raytone Biotechnology Co Ltd
Zhejiang Shapuaisi Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Myopia reports